A meta-analysis is suited to nullify the effects of n-3 PUFAs on cognitive function
Rachel A Murphy1, Rob Winwood1
1From DSM Nutritional Products, Parsippany, NJ (RAM, e-mail: rachel.murphy@dsm.com), and DSM Nutritional Products, Heanor, Derbyshire, United Kingdom (RW).
The American Journal of Clinical Nutrition
|March 4, 2015
Abstract
No abstract available in PubMed .
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
914
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
914
Atherosclerosis III: Management
613
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
613


